Jayamas Medica Industri TBK PT
Jayamas Medica Industri TBK PT is a medical equipment and supplies manufacturer and distributor in Indonesia, generating revenue primarily through the production and sale of medical devices and related healthcare products.
Business. Jayamas Medica Industri TBK PT (OMED.JK) is a healthcare company engaged in the medical equipment, supplies, and distribution industry. The firm operates within the Healthcare Services & Equipment sector, focusing on product sales. Headquarters and specific operating segment details are not provided in the available data. The company is primarily listed on the Indonesia Stock Exchange (IDX) under the ticker OMED.JK.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Jayamas Medica Industri TBK PT (OMED.JK) is a healthcare company engaged in the medical equipment, supplies, and distribution industry. The firm operates within the Healthcare Services & Equipment sector, focusing on product sales. Headquarters and specific operating segment details are not provided in the available data. The company is primarily listed on the Indonesia Stock Exchange (IDX) under the ticker OMED.JK.
Jayamas Medica Industri TBK PT maintains a strong liquidity position, with a current ratio of 10.36 and cash and equivalents amounting to 541.8 billion IDR. The company's debt-to-equity ratio is 0.08, indicating a conservative capital structure with minimal leverage. Free cash flow of 235.3 billion IDR supports operational flexibility and potential reinvestment.
Profitability metrics show a return on equity of 13.49% and a return on assets of 11.47%, both exceeding the industry median for medical equipment and supplies firms. Operating income of 409.4 billion IDR and net income of 366.9 billion IDR reflect strong margins, supported by a gross profit of 713.9 billion IDR.
The company's revenue is concentrated in its core medical equipment and supplies business, with no disclosed geographic diversification beyond Indonesia. This concentration may expose the company to regional economic and regulatory risks.
Growth trajectory is supported by a robust operating cash flow of 395.1 billion IDR and capital expenditures of -108.1 billion IDR, indicating ongoing investment in infrastructure and production capacity. Analysts have assigned a mean price target of 220.00 IDR, with a single "buy" recommendation and no "strong buy" or "hold" ratings.
Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt load and high cash reserves mitigate financial distress risk. No dilution pressure is currently evident, with basic and diluted shares outstanding aligned at 27.0 billion shares.
Recent events include consistent financial performance and no material adverse disclosures in the latest filings. The company's capital structure and operational metrics suggest a stable and well-managed business.
- Strong liquidity and low leverage support financial stability.
- High return on equity and assets indicate efficient capital use.
- Revenue concentration in Indonesia and core business may limit growth diversification.
- Analysts project a mean price target of 220.00 IDR with a single "buy" recommendation.
- No immediate liquidity or dilution risks are present.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 15,00 |
| Revenue | —no estimate | —no estimate | 2,29T IDR |
| Operating income | —no estimate | —no estimate | 424,0B IDR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Jayamas Medica Industri TBK PT Market data — financials · 2026-05-28
- Jayamas Medica Industri TBK PT Market data — analyst estimates · 2026-05-28